These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 1126452)

  • 21. Investigational new drug applications; clinical holds; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Dec; 63(239):68710-2. PubMed ID: 10187560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Sep; 75(188):59935-63. PubMed ID: 20879180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological products; bacterial vaccines and toxoids; implementation of efficacy review. Final rule and final order.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Jan; 69(2):255-67. PubMed ID: 14968793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Government regulations and the use of drugs.
    Hafkenschiel JH
    Calif Med; 1967 Aug; 107(2):159-63. PubMed ID: 4862066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sterility requirement for aqueous-based drug products for oral inhalation. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 May; 65(103):34082-9. PubMed ID: 11010719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulatory considerations for emergency use of non-USDA licensed vaccines in the United States.
    Hill RE; Foley PL; Carr MY; Elsken LA; Gatewood DM; Ludemann LR; Wilbur LA
    Dev Biol (Basel); 2003; 114():31-52. PubMed ID: 14677675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. International Conference on Harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1999 Aug; 64(159):44928-35. PubMed ID: 12356094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Environmental assessment requirements for live biological drugs.
    Sutton A
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S112-4; discussion S144-51. PubMed ID: 18181713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Foreign establishment registration and listing. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Nov; 66(228):59138-61. PubMed ID: 11776289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human); companion document to direct final rule. Food and Drug Administration, HHS. Proposed rule.
    Fed Regist; 1999 May; 64(93):26344-8. PubMed ID: 10558531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protection of human subjects; standards for institutional review boards for clinical investigations--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(17 pt 2):8958-79. PubMed ID: 10249529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment.
    Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigational new drug applications; clinical holds--FDA. Direct final rule.
    Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current regulatory issues in cell and tissue therapy.
    Burger SR
    Cytotherapy; 2003; 5(4):289-98. PubMed ID: 12944234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigational new drug applications; amendment to clinical hold regulations for products intended for life-threatening diseases and conditions. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Jun; 65(106):34963-71. PubMed ID: 11010726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Licensing veterinary biologics in the United States.
    Espeseth DA
    Dev Biol Stand; 1992; 79():17-25. PubMed ID: 1286752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measurement of final container residual moisture in freeze-dried biological products.
    May JC; Wheeler RM; Etz N; Del Grosso A
    Dev Biol Stand; 1992; 74():153-64. PubMed ID: 1592165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological products regulated under Section 351 of the Public Health Services Act; implementation of biologics license; elimination of establishment license and product license; correction--FDA. Proposed rule; correction.
    Fed Regist; 1998 Sep; 63(170):46718. PubMed ID: 10182705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.